Related Experiment Video
Updated: Jul 26, 2025
08:14
A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
Published on: August 28, 2018
8.2K
Targeting PCSK9 to tackle cardiovascular disease
Sandra Hummelgaard1, Joachim Pold Vilstrup2, Camilla Gustafsen2
1Department of Biomedicine, Aarhus University, Aarhus, Denmark.
Pharmacology & Therapeutics
|June 18, 2023
Summary
Lowering blood cholesterol with PCSK9 inhibitors effectively reduces cardiovascular disease risk. These therapies target PCSK9, a key regulator of LDL receptor degradation, offering a novel approach to managing hypercholesterolemia.
Area of Science:
- Biochemistry
- Genetics
- Cardiovascular Medicine
Background:
- Atherosclerotic cardiovascular disease (ASCVD), including coronary artery disease (CAD), is a leading cause of global mortality, driven by cholesterol plaque formation in arteries.
- Proprotein convertase subtilisin kexin/type 9 (PCSK9) is a critical regulator of cholesterol metabolism, controlling low-density lipoprotein (LDL) receptor levels in the liver.
Purpose of the Study:
- To review PCSK9 biology, including its structure and genetic mutations.
- To elaborate on current and developing PCSK9-lowering therapeutic strategies.
- To discuss future applications of PCSK9 inhibition beyond cardiovascular diseases.
Main Methods:
- Review of scientific literature on PCSK9 biology, genetics, and therapeutic development.
- Analysis of clinical data for approved and investigational PCSK9 inhibitors.
- Exploration of structural and genetic insights driving therapeutic design.
Main Results:
- Gain-of-function PCSK9 mutations cause familial hypercholesterolemia with high LDL-C and ASCVD risk.
- Loss-of-function PCSK9 mutations are associated with low LDL-C and CAD protection.
- Approved antibody-based PCSK9 inhibitors effectively reduce LDL-C and ASCVD events with a favorable safety profile.
Conclusions:
- PCSK9 is a validated therapeutic target for lowering LDL-C and reducing cardiovascular risk.
- PCSK9 inhibitors represent a significant advancement in managing hypercholesterolemia and preventing ASCVD.
- Further research into PCSK9 inhibition holds promise for treating other severe disorders.
Keywords:
Cardiovascular diseaseCholesterol-lowering agentsLDL-CLow-density lipoprotein receptorPCSK9PCSK9 inhibitorsMore Related Videos
Related Concept Videos
01:26Coronary Artery Disease IV: Preventive Measures
25
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
25
01:26Atherosclerosis III: Management
15
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
15
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
713
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
713
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
212
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
212
01:30Coronary Artery Disease I: Introduction
33
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
33
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K